Prospective observational study to assess the prognosis of patients with plasma cell neoplasms in Japa
Not Applicable
- Conditions
- ewly diagnosed plasma cell neoplasms
- Registration Number
- JPRN-UMIN000022099
- Lead Sponsor
- THE JAPANESE SOCIETY OF HEMATOLOGY
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 1100
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year overall survival in patients with symptomatic myeloma who have received drug therapies in novel drug era
- Secondary Outcome Measures
Name Time Method In patients with symptomatic myeloma who have received drug therapies: overall response rate(ORR), progression-free survival(PFS), time to next treatment(TNT), treatment-free interval(TFI), overall survival(OS) according to the difference of induction therapies, clinical stages, and cytogenetic risk groups in addition to exploring the incidence of second primary malignancies(SPM) after initial treatment In patients with plasma cell neoplasms except for symptomatic myeloma, systemic amyloidosis and POEMS syndrome, i.e., MGUS, smoldering myeloma, solitary plasmacytoma, multiple plasmacytoma and plasma cell leukemia: overall survival(OS), disease progression